Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
Uloženo v:
| Název: | Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern |
|---|---|
| Autoři: | Yu-Chi Chou, Luke Tzu-Chi Liu, Charles Chen, Chia-En Lien, Jinyi Cheng, Yi-Jiun Lin, Meei-Yun Lin, Wei-Cheng Lian, Tsun-Yung Kuo |
| Zdroj: | Clin Infect Dis |
| Informace o vydavateli: | Oxford University Press (OUP), 2021. |
| Rok vydání: | 2021 |
| Témata: | Major Articles and Commentaries, Adjuvants, Immunologic, Viral Envelope Proteins, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vaccines, Subunit, Animals, COVID-19, Humans, Antibodies, Viral, Antibodies, Neutralizing, Rats, 3. Good health |
| Popis: | Background Variants of concern (VoCs) have the potential to diminish the neutralizing capacity of antibodies elicited by vaccines. MVC-COV1901 is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine consisting of recombinant prefusion stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. We explored the effectiveness of MVC-COV1901 against the VoCs. Methods Serum samples were taken from rats and phase 1 clinical trial human subjects immunized with a low, medium, or high dose of MVC-COV1901. The neutralizing titers of serum antibodies were assayed with pseudoviruses coated with the SARS-CoV-2 spike protein of the wild-type (WT), D614G, Alpha, or Beta variants. Results Rats vaccinated twice with vaccine containing high doses of antigen retained high levels of neutralization activity against the Beta variant, albeit with a slight reduction compared to WT. After the third dose, neutralizing titers against the Beta variant were noticeably enhanced regardless of the amount of antigen used for immunization. In humans, vaccinated phase 1 subjects still showed appreciable neutralization abilities against the D614G, Alpha, and Beta variants, although neutralizing titers were significantly reduced against the Beta variant. Conclusions Two doses of MVC-COV1901 were able to elicit neutralizing antibodies against SARS-CoV-2 variants with an overall tendency of inducing higher immune response at a higher dose level. The neutralizing titers to the Beta variant in rats and humans were lower than those for WT and the Alpha variant. An additional third dose in rats was able to partially compensate for the reduction in neutralization against the Beta variant. We have demonstrated that immunization with MVC-COV1901 was effective against VoCs. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciab711 |
| Přístupová URL adresa: | https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab711/41088464/ciab711.pdf https://pubmed.ncbi.nlm.nih.gov/34739037 https://www.ncbi.nlm.nih.gov/pubmed/34739037 https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/zh/covidwho-1504298 https://europepmc.org/article/MED/34739037 https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab711/41088464/ciab711.pdf https://pubmed.ncbi.nlm.nih.gov/34739037/ |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Přístupové číslo: | edsair.doi.dedup.....33a55afdecf8dccaad8d6ee6f1fec2bc |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | Background Variants of concern (VoCs) have the potential to diminish the neutralizing capacity of antibodies elicited by vaccines. MVC-COV1901 is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine consisting of recombinant prefusion stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. We explored the effectiveness of MVC-COV1901 against the VoCs. Methods Serum samples were taken from rats and phase 1 clinical trial human subjects immunized with a low, medium, or high dose of MVC-COV1901. The neutralizing titers of serum antibodies were assayed with pseudoviruses coated with the SARS-CoV-2 spike protein of the wild-type (WT), D614G, Alpha, or Beta variants. Results Rats vaccinated twice with vaccine containing high doses of antigen retained high levels of neutralization activity against the Beta variant, albeit with a slight reduction compared to WT. After the third dose, neutralizing titers against the Beta variant were noticeably enhanced regardless of the amount of antigen used for immunization. In humans, vaccinated phase 1 subjects still showed appreciable neutralization abilities against the D614G, Alpha, and Beta variants, although neutralizing titers were significantly reduced against the Beta variant. Conclusions Two doses of MVC-COV1901 were able to elicit neutralizing antibodies against SARS-CoV-2 variants with an overall tendency of inducing higher immune response at a higher dose level. The neutralizing titers to the Beta variant in rats and humans were lower than those for WT and the Alpha variant. An additional third dose in rats was able to partially compensate for the reduction in neutralization against the Beta variant. We have demonstrated that immunization with MVC-COV1901 was effective against VoCs. |
|---|---|
| ISSN: | 15376591 10584838 |
| DOI: | 10.1093/cid/ciab711 |